Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

Rhea-AI Summary

Perspective Therapeutics (NYSE American: CATX) will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026, after the market closes. The earnings press release will be posted in the newsroom section of the company’s website.

Perspective Therapeutics is a radiopharmaceutical development company focused on cancer treatments using proprietary technology based on the alpha-generating isotope 212Pb. The company is advancing U.S. clinical-stage programs including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors), and is expanding its finished drug product supply network enabled by its 224Ra/212Pb generator platform.

Market Context

News ID 1055270 recorded a -2.84% reaction for the prior 1Q26 earnings event. That platform comparis...

Analysis

News ID 1055270 recorded a -2.84% reaction for the prior 1Q26 earnings event. That platform comparison frames this scheduled report against recent earnings history; the announced results and financial position remain the items to watch.

Key Figures

Reporting period: 2Q 2026 Reporting date: August 10, 2026 Alpha-generating isotope: 212Pb +1 more

4 metrics

Reporting period 2Q 2026 Financial results scheduled for reporting

Reporting date August 10, 2026 After the market closes

Alpha-generating isotope 212Pb Technology used to target cancer cells

Generator isotope platform 224Ra/212Pb Platform used to manufacture clinical drug product candidates

Previous Earnings Reports

5 past events · Latest: May 11 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 11	1Q26 earnings report	Negative	-2.8%	Wider net loss despite cash runway and continued clinical development progress
Mar 16	FY25 earnings report	Negative	-5.2%	Annual net loss and higher research spending accompanied clinical program progress
Feb 17	FY25 results scheduling	Neutral	+3.2%	Company scheduled its full-year results and business update for March 16
Nov 10	3Q25 earnings report	Negative	+0.0%	Clinical progress and safety updates accompanied materially higher operating expenses
Oct 24	3Q25 results scheduling	Neutral	+3.8%	Company scheduled third-quarter financial results and a business update

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific history showed reported earnings events producing negative or flat reactions, while earnings scheduling notices produced positive reactions.

Key Terms

radiopharmaceutical, theranostic, 212pb, 224ra/212pb generator platform

4 terms

radiopharmaceutical medical

"a radiopharmaceutical development company pioneering advanced treatments"

A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.

theranostic medical

"This "theranostic" approach enables visualization of the specific tumor"

A theranostic is a single medical approach or agent that combines diagnosis and treatment—using a test or imaging step to find patients likely to benefit, then delivering a targeted therapy tied to that same marker. For investors, theranostics can speed development, lower the chance of failed trials and concentrate sales on the right patients, like a smart key that both locates the correct lock and opens it, potentially improving clinical and commercial success.

212pb technical

"utilizes the alpha-generating isotope 212Pb to deliver powerful radiation"

212Pb is a radioactive form of the metal lead used as a delivery vehicle in certain cancer treatments; it decays to produce short-range, high-energy particles that can destroy tumor cells near where it lodges. For investors, it matters because drugs using 212Pb combine scientific promise with regulatory, manufacturing and safety challenges—similar to a precision-guided tool that can be powerful but costly and complex to develop and commercialize.

224ra/212pb generator platform technical

"proprietary 224Ra/212Pb generator platform used to manufacture"

A 224Ra/212Pb generator platform is a device and production method that creates short‑lived radioactive isotopes—radium‑224 and its decay product lead‑212—used to make targeted alpha therapy drugs for cancer. Think of it like a small factory that generates a powerful, short‑lived ingredient on demand so clinics or drug makers can attach it to targeting molecules; it matters to investors because it affects the supply, cost, and scalability of proprietary radiopharmaceutical treatments and related commercial opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the expected benefits of the Company’s technologies and product candidates; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s preclinical and clinical development plans and clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and development activities; economic and market conditions may worsen; regulatory agencies may issue decisions that negatively impact the Company’s product candidates and clinical development plans; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

FAQ

When will Perspective Therapeutics (CATX) report its Q2 2026 financial results?

Perspective Therapeutics will report its Q2 2026 financial results on Monday, August 10, 2026, after the market closes. According to the company, the related press release will be posted in the newsroom section of its website for investor access and review.

How can investors access Perspective Therapeutics’ Q2 2026 earnings press release for CATX?

Investors can access the Q2 2026 earnings press release on Perspective Therapeutics’ website in the newsroom press releases section. According to the company, the update will be posted there after the market closes on August 10, 2026, for public viewing.

What does Perspective Therapeutics (CATX) focus on in its cancer treatment pipeline?

Perspective Therapeutics focuses on radiopharmaceutical treatments using the alpha-generating isotope 212Pb to target cancer cells. According to the company, it is developing a theranostic approach combining targeted therapies and imaging to personalize treatment, potentially improve efficacy, and minimize toxicity across multiple tumor types.

Which clinical-stage programs is Perspective Therapeutics (CATX) currently advancing?

Perspective Therapeutics is advancing clinical-stage programs including VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors. According to the company, these U.S. programs use its 212Pb-based radiopharmaceutical technology and are part of its broader oncology portfolio.

What is the theranostic approach used by Perspective Therapeutics (CATX)?

Perspective Therapeutics uses a theranostic approach that combines targeted imaging and therapy based on the same tumor-seeking moieties. According to the company, this enables tumor visualization and subsequent treatment, with the goal of personalizing care, optimizing patient outcomes, and reducing treatment-related toxicity.

How does Perspective Therapeutics’ 224Ra/212Pb generator platform support its drug supply?

Perspective Therapeutics uses a proprietary 224Ra/212Pb generator platform to manufacture clinical drug product candidates. According to the company, this platform supports an expanding regional network to deliver finished, patient-ready drug product candidates for clinical trials and, if approved, for future commercial operations.